174 related articles for article (PubMed ID: 20585344)
1. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
Furusato B; Tan SH; Young D; Dobi A; Sun C; Mohamed AA; Thangapazham R; Chen Y; McMaster G; Sreenath T; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):228-37. PubMed ID: 20585344
[TBL] [Abstract][Full Text] [Related]
2. ERG oncogene modulates prostaglandin signaling in prostate cancer cells.
Mohamed AA; Tan SH; Sun C; Shaheduzzaman S; Hu Y; Petrovics G; Chen Y; Sesterhenn IA; Li H; Sreenath T; McLeod DG; Dobi A; Srivastava S
Cancer Biol Ther; 2011 Feb; 11(4):410-7. PubMed ID: 21178489
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ERG responsive proteome in prostate cancer.
Tan SH; Furusato B; Fang X; He F; Mohamed AA; Griner NB; Sood K; Saxena S; Katta S; Young D; Chen Y; Sreenath T; Petrovics G; Dobi A; McLeod DG; Sesterhenn IA; Saxena S; Srivastava S
Prostate; 2014 Jan; 74(1):70-89. PubMed ID: 24115221
[TBL] [Abstract][Full Text] [Related]
4. Identification of a cell of origin for human prostate cancer.
Goldstein AS; Huang J; Guo C; Garraway IP; Witte ON
Science; 2010 Jul; 329(5991):568-71. PubMed ID: 20671189
[TBL] [Abstract][Full Text] [Related]
5. Study of matrix metalloproteinases and their inhibitors in prostate cancer.
Escaff S; Fernández JM; González LO; Suárez A; González-Reyes S; González JM; Vizoso FJ
Br J Cancer; 2010 Mar; 102(5):922-9. PubMed ID: 20160732
[TBL] [Abstract][Full Text] [Related]
6. Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines.
Nhili R; Peixoto P; Depauw S; Flajollet S; Dezitter X; Munde MM; Ismail MA; Kumar A; Farahat AA; Stephens CE; Duterque-Coquillaud M; David Wilson W; Boykin DW; David-Cordonnier MH
Nucleic Acids Res; 2013 Jan; 41(1):125-38. PubMed ID: 23093599
[TBL] [Abstract][Full Text] [Related]
7. Detection of fusion gene transcripts in the blood samples of prostate cancer patients.
Yu YP; Liu S; Nelson J; Luo JH
Sci Rep; 2021 Aug; 11(1):16995. PubMed ID: 34417538
[TBL] [Abstract][Full Text] [Related]
8. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
9. Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S; Gärtner M; Freudenthaler F; Bauer M; Kluth M; Salomon G; Heinzer H; Graefen M; Bokemeyer C; Simon R; Sauter G; Schlomm T; Wilczak W
Mod Pathol; 2013 Jan; 26(1):106-16. PubMed ID: 22899295
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
Loeb S; Bruinsma SM; Nicholson J; Briganti A; Pickles T; Kakehi Y; Carlsson SV; Roobol MJ
Eur Urol; 2015 Apr; 67(4):619-26. PubMed ID: 25457014
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
[TBL] [Abstract][Full Text] [Related]
12. The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Pernigoni N; Guo C; Gallagher L; Yuan W; Colucci M; Troiani M; Liu L; Maraccani L; Guccini I; Migliorini D; de Bono J; Alimonti A
Nat Rev Urol; 2023 Dec; 20(12):706-718. PubMed ID: 37491512
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.
Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.
Jayakrishnan R; Schafer C; Tan SH
Am J Clin Exp Urol; 2023; 11(2):79-102. PubMed ID: 37168942
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase A: An emerging therapeutic target in prostate cancer.
Chen CH; Wu BJ
Front Oncol; 2023; 13():1137050. PubMed ID: 36860320
[TBL] [Abstract][Full Text] [Related]
16. Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8.
Bakbak H; Sayar E; Kaur HB; Salles DC; Patel RA; Hicks J; Lotan TL; De Marzo AM; Gulati R; Epstein JI; Haffner MC
Hum Pathol; 2022 Dec; 130():18-24. PubMed ID: 36309296
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of immunohistochemical markers alpha methyl acyl coA racemase (AMACR) and Ets related gene (ERG) in prostate cancer.
Stephen N; Badhe BA
Int J Clin Exp Pathol; 2022; 15(9):364-372. PubMed ID: 36237639
[TBL] [Abstract][Full Text] [Related]
18. Downstream Regulatory Network of MYBL2 Mediating Its Oncogenic Role in Melanoma.
Zhong F; Liu J; Gao C; Chen T; Li B
Front Oncol; 2022; 12():816070. PubMed ID: 35664780
[TBL] [Abstract][Full Text] [Related]
19. The evolving landscape of prostate cancer somatic mutations.
Cotter K; Rubin MA
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S13-S24. PubMed ID: 35657155
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
